Blockbuster Drugs

Click here to load reader

download Blockbuster Drugs

of 18

  • date post

    06-Apr-2018
  • Category

    Documents

  • view

    215
  • download

    0

Embed Size (px)

Transcript of Blockbuster Drugs

  • 8/3/2019 Blockbuster Drugs

    1/18

    BLOCKBUSTER DRUGS

    END OF THE ERA?

    YET NEW AVENUES..

    1MBA(pharma tech) IVth YEAR

    KAKULI SINHA

    ROLL -18

    DIV- A

  • 8/3/2019 Blockbuster Drugs

    2/18

    2MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    3/18

    1. END OF BLOCKBUSTERERA.

    2. DRY R&D PIPELINE

    3. DRUG PRICING PRESSURES

    4. STRICT REGULATORY

    REQUIREMENTS

    PHARMACEUTICAL

    INDUSTRY :

    DRAMATIC CHANGE

    3MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    4/18

    4MBA(pharma tech) IVth YEAR

    THE DRY DESERT OF PATENT EXPIRATION

  • 8/3/2019 Blockbuster Drugs

    5/18

    5MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    6/18

    6MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    7/18

    MBA(pharma tech) IVth YEAR 7

    Fig: This figure demonstrates the sharp fall(26.78%) in the stock price of Merck, on

    September 30, 2004 .

    Source: 12 PR catastrophe that crushed company shareholders, Alyson shontell,

    Oct 30,2010

  • 8/3/2019 Blockbuster Drugs

    8/18

    WHAT NEXT???

    SHIFT FROM MARKET SHARE CAPTURE TO MARKET

    CREATION.

    ADOPT DIFFERENTIATED STRATEGIES AND BUSINESS

    MODEL.

    8MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    9/18

    ENSURING ACCESSIBILITY.

    STRENGTHEN SALES AND MARKETING

    CAPABILITIES.

    9MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    10/18

    INNOVATION AND NEW TECHNOLOGIES

    UNTAPPED POTENTIAL OF BIOTECHNOLOGY Excellent alternative to dried pipelines

    improved safety profiles, efficacies and cost to

    benefit ratio The biologics sector is experiencing robust

    growth. The rate of sale of biotech products is

    double that of pharmaceuticals in the last year

    10MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    11/18

    Biologics are almost impossible to replicate becauseeach one of it is uniquely dependent on the cell line

    and the manufacturing process used.

    There is no regulatory norm through which FDA can

    grant biosimilars or follow-on biologics approval

    11MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    12/18

    PHARMACOGENOMICS AND PERSONALISED

    MEDICINE

    right drug for the right patient.

    It describes how an individuals genetic

    inheritance affects bodys response to drugs.

    12MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    13/18

    GENE VARIANTS IDENTIFIED

    BIOMARKERS- STRATIFICATION INTO SUBGROUPS.

    BEST TREATMENT FOR EACH SUBGROUP

    13MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    14/18

    CANCER: SETTING THE BEST EXAMPLE

    14MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    15/18

    15MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    16/18

    CONCLUSION

    Pharmaceutical firms must refocus its energy to

    discover superior drugs that will genuinely help

    sick people.

    . Biotech and personalized drugs offer an ideal

    platform to do this.

    16MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    17/18

    Two developments will help the industry reinvigorate its

    pipeline:

    First, the widespread recognition of the fact that the

    commercial potential of drugs that fit the conventional

    therapeutic product profile is declining.

    Second, the increase in the understanding and application

    of the molecular sciences.

    17MBA(pharma tech) IVth YEAR

  • 8/3/2019 Blockbuster Drugs

    18/18

    18MBA(pharma tech) IVth YEAR